Skip to content

YPOG advises lead investor Vesalius Biocapital on Series C financing round of HepaRegeniX

Reading time: 1 minute

Berlin, July 2024 – YPOG advised the lead investor Vesalius Biocapital IV on the Series C financing round of HepaRegeniX GmbH. Existing investors such as Novo Holdings, Boehringer Ingelheim Venture Fund and High-Tech Gründerfonds also participated in the investment.

HepaRegeniX GmbH is a clinical stage company developing novel therapies for the treatment of acute and chronic liver diseases. Since its launch in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel molecular target Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4). HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4). This substance has the potential to significantly support liver regeneration in patients with liver metastases or primary liver tumors.

The new funding will support the Phases Ib/ IIa clinical trial focused on improving liver healing and preventing liver failure.

Team

Dr. Martin Schaper (Lead, Transactions), Partner, Berlin
Dr. Lutz Schreiber (IP/IT/Data Protection), Partner, Hamburg
Benjamin Müller (Transactions), Associate, Berlin
Matthias Treude (IP/IT/Data Protection), Associate, Hamburg
Cyra Dittberner (Transactions), Associate, Berlin

About Vesalius Biocapital IV

Vesalius Biocapital is an established European life sciences venture capital investor with a long track record of consistent returns, investing in best/first-in-class European Biopharma and HealthTech companies.

The company is investing in appealing, later-stage companies in drug development, medical devices & diagnostics and eHealth / mHealth, predominantly in Europe. Its portfolio companies address unmet medical & market needs and operate on the basis of strong intellectual property protection.

 

Download Press Release: YPOG advises lead investor Vesalius Biocapital on Series C financing round of HepaRegeniX

About us

YPOG stands for You + Partners of Gamechangers – forward-thinking legal and tax advice. Supporting companies that are focused on emerging technologies, YPOG embraces change as an opportunity to develop cutting-edge solutions. The YPOG team offers comprehensive expertise in the areas of Funds, Tax, Transactions, Corporate, Banking, Regulatory + Finance, IP/IT/Data Protection, Litigation, and Corporate Crime + Compliance + Investigations. YPOG is one of the leading law firms in Germany for venture capital, private equity, fund structuring, and the implementation of distributed ledger technology (DLT) in financial services. Both the firm and its partners are regularly recognized by renowned national and international publications such as JUVE, Best Lawyers, Chambers and Partners, Leaders League, and Legal 500. YPOG is home to more than 150 experienced attorneys, tax advisors and tax specialists as well as a notary, working across offices in Berlin, Hamburg, Cologne, and Munich. 

Further information: www.ypog.law/en/ and www.linkedin.com/company/ypog

More articles

Explore all